Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline manufacturing s.p.a. - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 500mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline manufacturing s.p.a. - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 1000mg

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - ceftazidime pentahydrate - powder for solution for injection - ceftazidime pentahydrate 1 g - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ceftazidime pentahydrate, quantity: 2.328 g (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate - fortum is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials , but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. respiratory tract infections: for example, pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections: for example, otitis media, mastoiditis. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. skin and soft tissue infections: for example, erys

Malta - English - Medicines Authority

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - powder for solution for injection - ceftazidime pentahydrate 1 g - antibacterials for systemic use

Canada - English - Health Canada

seagen inc. - enfortumab vedotin - powder for solution - 20mg - enfortumab vedotin 20mg - antineoplastic agents

Canada - English - Health Canada

seagen inc. - enfortumab vedotin - powder for solution - 30mg - enfortumab vedotin 30mg - antineoplastic agents

Malta - English - Medicines Authority

glaxo operations uk limited - ceftazidime - powder for solution for injection - ceftazidime 1 g - antibacterials for systemic use

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - ceftazidime pentahydrate eqv ceftazidime - injection, powder, for solution - 1 g/vial - ceftazidime pentahydrate eqv ceftazidime 1 g/vial

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - enfortumab vedotin, quantity: 30 mg - injection, powder for - excipient ingredients: polysorbate 20; histidine hydrochloride monohydrate; histidine; trehalose dihydrate - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand-1 inhibitor.